Last updated on May 2020

Study of DS-8201a an Antibody Drug Conjugate for Advanced Breast Cancer Patients With Biomarkers Analysis

Brief description of study

Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.

Detailed Study Description

The main objective is to evaluate the anti-tumor activity of DS-8201a in three cohorts of advanced breast cancer patients:

  • Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)
  • Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)
  • Cohort 3: HER2 non-expressing (IHC0+)

Clinical Study Identifier: NCT04132960

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.